Novo Nordisk's CagriSema outperforms tirzepatide in weight loss trials, boosting market challenge

In a significant breakthrough, Novo Nordisk’s experimental drug CagriSema has demonstrated superior weight loss results compared to tirzepatide in late-stage trials, signalling a potential shift in the competitive landscape of metabolic disease treatments. Novo Nordisk said on Monday that its…















